Our Story
We are medical researchers, AI experts, and industry leaders who have been personally touched by cancer, grounding our work in urgency. Across oncology, we kept seeing the same pattern: promising evidence for new cancer uses of low-cost generic drugs, but little awareness, no commercial sponsor, and no clear path forward.
These treatments were published, accessible, and in some cases supported by rigorous clinical data. Yet because no company stands to profit from off-patent drugs, they had no one to carry them across the finish line to patients.
The result:
patients miss meaningful treatment opportunities
clinicians lack clear, trusted evidence
health systems lose access to low-cost, high-value options
This is not a scientific gap. It’s a structural one.
Reboot Rx was founded to change this.
Founder’s Story
Laura Kleiman, PhD
Laura Kleiman, PhD, experienced this gap firsthand when she was running a data science research center at the Dana-Farber Cancer Institute. Her mother was diagnosed with cancer and became a patient at Dana-Farber. While searching the literature for treatment options, her family found promising studies on repurposed therapies that might help patients like her mother. Yet no one was moving them forward.
After her mother passed away, Laura decided to dedicate her career to solving this problem. She founded Reboot Rx, a nonprofit organization focused on using AI-powered evidence synthesis to surface repurposing opportunities and advance them. Drawing on her background in computational and systems biology (MIT) and translational oncology (Massachusetts General Hospital and Harvard Medical School), Laura has led Reboot Rx since its founding. Her work has been recognized by programs including 40 Under 40 in Cancer, the MassNextGen Initiative, and Extraordinary Women Advancing Healthcare.
Cancer breakthroughs don’t always require new drugs.
Sometimes they require doing more with drugs we already have.
How We Work Today
We are a nonprofit, independent of industry, focused on advancing evidence-based, affordable cancer treatments that the market overlooks.
Our work blends large-scale evidence analysis with scientific, clinical, and health system partnerships to help repurposed generics move toward clinical consideration. We prioritize treatments that have potential to deliver the greatest benefit for the greatest number of patients.
Our belief is simple:
When strong evidence exists for an effective, affordable cancer treatment, clinical consideration shouldn’t depend on profitability.
Early Recognition
Reboot Rx’s approach has been recognized by leading innovation and health organizations, including:
